BMO Capital analyst Evan Seigerman raised the firm’s price target on Regeneron (REGN) to $985 from $960 and keeps an Outperform rating on the shares. The Eylea HD injection approval by the FDA announced on Friday comes earlier than expected and should be seen as a significant step for Regeneron to solidify its ophthalmology franchise, the analyst tells investors in a research note. This could allow for transitioning of new patient starts to Eylea HD ahead of new Eylea biosimilar entrants and increasing competition from Roche’s (RHHBY) Vabysmo, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN:
- Regeneron Stock (NASDAQ:REGN): Analysts are Bullish Post FDA Approval
- Regeneron price target raised to $1,050 from $950 at Oppenheimer
- Regeneron price target raised to $925 from $900 at Barclays
- Regeneron announces FDA approval of Eylea HD for three indications
- EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)